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Motor signs during the course of
Alzheimer disease
N. Scarmeas, MD; G.M. Hadjigeorgiou, MD; A. Papadimitriou, MD; B. Dubois, MD; M. Sarazin, MD;
J. Brandt, PhD; M. Albert, PhD; K. Marder, MD, MPH; K. Bell, MD; L.S. Honig, MD, PhD;
D. Wegesin, PhD; and Y. Stern, PhD
Abstract—Background: Motor signs (MOSIs) are common in Alzheimer disease (AD) and may be associated with rates of
cognitive decline, mortality, and cost of care. Objective: To describe the progression and identify predictors of individual
MOSIs in AD. Methods: A cohort of 474 patients with AD at early stages was followed semiannually for up to 13.1 years
(mean 3.6 years) in five centers in Europe and the United States. MOSIs were rated using a standardized portion of the
Unified Parkinson’s Disease Rating Scale. Overall, 3,030 visits/assessments of MOSIs (average 6.4/patient) were per-
formed. Prevalence and incidence rates were calculated, and cumulative risk graphs were plotted for individual non-drug-
induced MOSI domains. Rates of change over time taking into account potential covariates were also estimated. With use
of each MOSI domain as outcome in Cox models, predictors of MOSI incidence were identified. Results: At least one MOSI
was detected in 13% of patients at first examination and in 36% for the last evaluation. Total MOSI score increased at an
annual rate of 3% of total possible score. Rates of annual change for speech/facial expression (4%), rigidity (2.45%),
posture/gait (3.9%), and bradykinesia (3.75%) were of similar magnitude, and their occurrence increased from first (3 to
6%) to last (22 to 29%) evaluation. Tremor was less frequent throughout the course of the disease (4% at first and 7% at
last evaluation) and worsened less (0.75% increase/year). Conclusions: Most motor signs occur frequently and progress
rapidly in Alzheimer disease. Tremor is an exception in that it occurs less frequently and advances at slower rates.
NEUROLOGY 2004;63:975–982
Many studies have reported that motor signs
(MOSIs) are commonly observed in Alzheimer dis-
ease (AD) and that they increase in frequency and
severity over time. These MOSIs may result from
different underlying mechanisms, and although they
are usually considered as resulting from pathologic
changes of the extrapyramidal system, their exact
anatomic location is not clear. For this reason, in
this article, we use the term “MOSI” to refer to what
is usually described in the literature as extrapyrami-
dal signs or parkinsonian signs or parkinsonism. In-
formation about the presence of MOSIs in AD is
important because they may predict cognitive
decline,1-3 institutionalization,4-6 and death.5,7-10 In
addition, as compared with AD patients without
MOSIs, AD patients with MOSIs have on average
$7,394 higher annual total cost of care (a 1-point
increase in an MOSI scale has been associated with
an annual increase of $827 in total costs of care).11
However, there is large variability in reported fre-
quencies for various stages of the disease. For exam-
ple, in a review of clinical series published over a
10-year period, frequency of MOSIs in AD ranged
from 6% to 50%.12 Some of this inconsistency de-
rives from methodologic differences including vari-
able definitions of MOSIs, inclusion or exclusion of
subjects who used neuroleptics, use of standardized
scales vs just clinical evaluation, inclusion of sub-
jects at varying stages of disease, variable levels of
participation at follow-up, etc. Additionally, most in-
formation about MOSIs in AD is inferred from cross-
sectional studies; although AD is a progressive
disease, relatively little information is available from
longitudinal studies tracking MOSI changes over
time. Also, most studies examine MOSIs globally,
and only few reports have focused on individual sub-
sets of MOSIs.6 With few exceptions,13 MOSIs are
treated dichotomously (either present or absent),
limiting information about the full range of motoric
changes that occur over time in AD. Finally, little is
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known about specific factors that influence the occur-
rence or rate of progression of MOSIs in AD.
To investigate these issues, we analyzed data from
a large, multicenter cohort of patients with probable
AD that included patients from very early disease
stages and included semiannual, standardized as-
sessment of MOSIs for up to 13 years of follow-up.
We first attempted to characterize the occurrence of
different types of MOSIs and MOSIs overall during
the natural course of AD. Taking advantage of the
fact that five different centers participated in this
study, we examined whether development of MOSIs
in AD differs for populations of different ethnic ori-
gin. We also investigated the existence of other fac-
tors that may predict which AD patients will develop
MOSIs. We finally explored rates of change of differ-
ent types of MOSIs and MOSIs overall over the
course of AD, controlling for factors that may affect
these rates.
Methods. Subjects. In these analyses, we include subjects
from two Predictors Study cohorts.14 For the first cohort, patients
were recruited and studied at three sites in the USA: Columbia
University (NY), Johns Hopkins University (Baltimore, MD), and
Harvard University (Boston, MA). For the second cohort, two ad-
ditional sites in the European Union were added: Hospital de la
Salpetriere (Paris, France) and University of Thessaly (Larissa,
Greece). The study was approved by the appropriate local institu-
tional review boards.
The inclusion and exclusion criteria as well as the evaluation
procedures of the Predictors Study have been fully described else-
where.14 In brief, patients met Diagnostic and Statistical Manual
for Mental Disorders (3rd rev. ed.) criteria for primary degenera-
tive dementia of the Alzheimer type and National Institute of
Neurologic Disorders and Stroke/Alzheimer’s Disease and Related
Disorders Association criteria for probable AD. Enrollment re-
quired a modified Mini-Mental State (mMMS) score of 30 (max-
imum mMMS score, 57), which is equivalent to a score of
approximately 16 on the Folstein Mini-Mental State Examina-
tion (MMSE).15,16 Exclusion criteria were diagnosis of Parkinson
disease or parkinsonism at any time prior to the onset of intellec-
tual decline, clinical or historical evidence of stroke, history of
alcohol abuse or dependence, any electroconvulsive treatment
within 2 years of recruitment or 10 electroconvulsive sessions at
any time, and history or current clinical evidence of schizophrenia
or schizoaffective disorder that started before the onset of intellec-
tual decline. Each consecutive patient who met the inclusion but
not the exclusion criteria of the study was included, except for
those who did not consent to participate or who lived too far and
were unable to return to the hospital for regular follow-up.
Patients’ clinical diagnosis was revisited yearly, and only sub-
jects who were consistently over time thought to have clinical AD
were used for analyses. Subjects of this cohort were classified as
having clinical AD (and not Lewy body dementia) because MOSIs
did not develop until later stages of their disease.
Evaluation measures. At the initial visit, various demo-
graphic (age, ethnicity, sex, education, etc.) and disease severity
features were assessed. APOE studies were not an original compo-
nent of the Predictors Study because when data collection was
initiated, APOE testing was not available. Beginning in the sixth
year of the study, however, available subjects were approached to
contribute blood samples for analyses. The pattern of each sub-
ject’s APOE isoforms was determined using the method of Hix-
son.17 For the purposes of analysis, patients were dichotomized
into two groups: those carrying an 4 allele (either two 4 alleles
[4/4] or one 4 allele [3/4 or 2/4]) and those carrying no 4
alleles (3/3 or 2/2 or 3/2).
Neurologic and mental status examinations were conducted at
study entry and at 6-month intervals thereafter. The cognitive
function measure used for the analysis was the mMMSE (in En-
glish for the US sites and in French- and Greek-translated ver-
sions for the European Union sites).15,16,18 This is a 57-point version
of the original Folstein MMSE15 that includes the addition of digit
span forward and backward,19 two additional calculation items,
recall of the current and four previous presidents of the United
States, confrontation naming of 10 items from the Boston Naming
Test,20 one additional sentence to repeat, and one additional figure
to copy. Functional capacity was assessed using the Blessed De-
mentia Rating Scale (BDRS) Parts I and II.21 The range is be-
tween 0 and 17, with higher scores indicating worse functional
status.
MOSIs were assessed by trained examiners using a modified
Unified Parkinson’s Disease Rating Scale (UPDRS) that has good
interrater reliability properties in dementia populations.22 More
specifically, excellent agreement for all five rigidity items and gait
and fair to good agreement for speech, facial expression, posture,
and body bradykinesia/hypokinesia have been demonstrated with
use of this scale.22 Because no tremor was detected in that study,
adequate assessment of tremor reliability could not be performed,
but good to excellent reliabilities for the UPDRS tremor items
have been demonstrated in other studies.23 The reliability proper-
ties of the scale have been demonstrated for raters in the primary
site of this study (Columbia University); no among-recruitment
center assessments were performed because across-center reliabil-
ity in a particular point in time would be of limited value, given
the long duration of this study and continuous change of raters
over time.
The following 11 items were rated on a scale of 0 to 4 (with 0
being normal and 4 indicating maximum impairment): speech,
tremor at rest (in any limb), facial expression, neck rigidity, right
arm rigidity, left arm rigidity, right leg rigidity, left leg rigidity,
posture, gait, body bradykinesia/hypokinesia. The 11 items were
grouped into the following five domains: speech/facial expression
(two items, range 0 to 8), tremor (one item, range 0 to 4), rigidity
(five items, range 0 to 20), posture/gait (two items, range 0 to 8),
and bradykinesia (one item, range 0 to 4). Total MOSI score was
used in the analyses in two different ways. First, a dichotomous
MOSI variable was used: total score of 2 vs total score of 2.
The reasons for this cutoff are as follows: 1) we previously demon-
strated good interrater reliability for severity at least mild to
moderate (score of 2, i.e., 1, which indicates slight severity)22;
2) this level of severity is also more likely to be noted by the
average clinician. Second, to make better use of the full range of
the recorded data, total MOSI score as a continuous variable was
used (range 0 to 44). The domain subscores were also used in two
different ways: dichotomous form (domain score of 2 vs domain
score of 2) and continuous form.
Only non-drug-induced MOSIs were considered for these anal-
yses. More specifically, at every 6-month visit, the following two
items were recorded: 1) Was the patient on medications that could
cause MOSIs (such as neuroleptics)? 2) Had the patient taken
such medications in the past but did not continue to do so? If there
was an affirmative answer to either of the two questions, the
particular subject-evaluation was excluded from the analyses.
Statistical analyses. At first, we calculated prevalence of
MOSIs at initial and last visits. Because patients were followed up
for different lengths of time, we calculated incidence rates as
follows: We took the total number of new cases (patients with
new-onset MOSIs) during the follow-up period, divided it by the
sum of follow-up time for all patients being followed up (until
either development of MOSIs or last follow-up without MOSIs),
and multiplied the result by 1,000. The resulting incidence rates
express number of patients with new onset of MOSIs per 1,000
person-years of observation. We calculated and plotted survival
curves with use of Kaplan–Meier survival analyses.24 All the
above was done for MOSIs overall as well as for each MOSI
domain. We used the dichotomous forms of the MOSI variables for
these analyses.
Because of the clustered nature of the data and to make better
use of the full range of the MOSI scores and characterize the rates
of change of the MOSI scores, we also used generalized estimating
equations (GEEs)25 to investigate potential predictors of MOSI.
GEEs take into account the multiple visits per subject and the fact
that the characteristics of the same individual over time (his/her
MOSI score for this analysis) are likely to be correlated. The
repeated measures for each subject are treated as a cluster. Total
MOSI score (in its continuous form) was the dependent variable in
this model. The model initially considered the effect of time for
every MOSI evaluation (in years since the initial evaluation). A
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significant time effect indicates a marked change in MOSI scores
over time. In a subsequent model, we simultaneously included the
following predictors: time, age at intake in the study, sex, educa-
tion in years, APOE genotype, mMMS score at initial evaluation,
BDRS score at initial evaluation, and MOSI score at initial evalu-
ation. A significant time effect in this model indicates a marked
change in MOSI scores over time, controlling for the other predic-
tors in the model. Similar GEE models were built for each MOSI
domain.
Subsequently, we investigated potential predictors of incident
MOSI. First, we used Cox proportional hazards analyses26 with
total MOSIs (dichotomous form) as the outcome and duration (in
years) between the initial visit and either development of MOSIs
or last evaluation without MOSIs as the timing variable. Patients
with MOSIs at first evaluation were not included in the Cox
analyses. The following predictors were simultaneously included
in the model: age at intake in the study, sex, education in years,
APOE genotype, recruitment center (as a dummy variable),
mMMSE score at initial evaluation, and BDRS score at initial
evaluation. To identify potential predictors of individual MOSI
domains, we calculated similar Cox models with each MOSI do-
main as the outcome.
Results. Overall, 474 subjects with AD, followed for up
to 13.11 years, were included in the study. Basic demo-
graphic and clinical information are presented in table 1.
There were 3,030 visits/assessments of MOSIs (up to 26/
patient, with average 6.4/patient). During the period each
subject was followed, missed visits were rare: Less than
18% missed more than one semiannual visit, and 9%
missed more than two. Rates of missing individual MOSI
items (when MOSI scale was administered) ranged be-
tween 0.7 and 4.5%.
Prevalences of MOSIs (dichotomous, present vs absent)
at first, last, and any evaluation and incidence rates are
presented in table 2, and cumulative risk curves are plot-
ted in figure 1. Frequencies of all MOSI domains increase
as disease chronicity increases (more frequent last as com-
pared with first evaluation). More specifically, the preva-
lence of any MOSI per year of follow-up was as follows: 1st
year 18%, 2nd year 19%, 3rd year 25%, 4th year 33%, 5th
year 46%, 6th year 41%, 7th year 39%, 8th year 47%, 9th
year 90%, 10th year 67%, 11th year 62%, 12th year 64%,
13th year 71%. All MOSI domains occurred with roughly
the same frequency (3 to 6% at first evaluation and 7 to
24% at last evaluation), with the exception of resting
tremor, which was clearly less frequent at last evaluation
(7%). Incidence rates were of roughly the same magnitude
for speech/facial expression, rigidity, posture/gait, and bra-
dykinesia (82 to 111 new cases with the above symptoms
per 1,000 person-years of follow-up) and lower for tremor
(29 new cases per 1,000 person-years of follow-up). This is
graphically represented in the cumulative risk curves that
indicate that there is a gradual increase in the probability
of having MOSIs as the disease progresses. The slope of
the curve is less steep for resting tremor.
If all patients, including those whose MOSIs could be
possibly drug induced, were included, the corresponding
frequencies of any MOSIs are even higher: baseline evalu-
ation 64 (14%), last evaluation 204 (43%), any evaluation
249 (53%). It is possible that motoric abnormalities in pa-
tients taking MOSI-inducing medication are not com-
pletely caused by medications but are also partially
accounted for by AD-related enhanced sensitivity to neuro-
leptics. However, because it is not possible to separate the
relative contribution of these two factors and to increase
our confidence that the occurrence of MOSIs in the current
study is strictly related to the underlying disease process,
we analyze only non-drug-induced MOSIs.
The GEE models can better assess changes over time
and assign significance, adjusting for covariates. In the
initial GEE model, there was an increase of all MOSIs
(continuous score) over time (  1.31, p  0.0001). This
corresponds to 1.34 units of higher MOSI score per year of
follow-up. Taking into account that total MOSI score
ranges from 0 to 44, this corresponds to 3% of the total
possible score. In the adjusted GEE model, when simulta-
neously controlling for age, sex, education, APOE, baseline
mMMS, baseline BDRS, and baseline MOSI score, there
was still an increase of MOSI score over time, which was of
similar magnitude (  1.32, p  0.0001).
In the unadjusted models, there was an increase of
speech/facial expression (  0.31, p  0.0001), rigidity
(  0.53, p  0.0001), posture/gait (  0.30, p  0.0001),
and bradykinesia (  0.15, p  0.0001) scores over time,
whereas the increase was considerably smaller for tremor
(  0.02, p  0.02). In the models adjusted for age, sex,
education, APOE, baseline mMMS, baseline BDRS, and
baseline MOSI domain score, the results were similar: in-
Table 1 Demographic and clinical characteristics of patients
Age at study entry, mean (SD), y 74.1 (8.8)
Men/women, n (%) 191 (40)/281 (60)
Education, mean (SD), y 13.3 (3.8)
No 4 alleles/one or two 4 alleles, n (%) 95 (44)/119 (56)
Recruitment center
New York, n (%) 178 (38)
Baltimore, n (%) 124 (26)
Boston, n (%) 114 (23)
Paris, n (%) 37 (8)
Larissa, n (%) 21 (5)
mMMS at study entry, mean (SD) 39.4 (6.2)
BDRS at study entry, mean (SD) 3.5 (2.0)
Dead during follow-up, n (%) 226 (48)
Duration of follow-up, mean (SD), y 3.6 (3.1)
mMMS  Modified Mini-Mental State; BDRS  Blessed Demen-
tia Rating Scale.
Table 2 Prevalence for baseline, last, and any evaluation and
















16 (3) 92 (20) 102 (22) 82
Tremor 17 (4) 34 (7) 51 (11) 29
Rigidity 28 (6) 86 (18) 122 (26) 95
Posture/gait 26 (6) 112 (24) 133 (29) 111
Bradykinesia 19 (4) 95 (20) 113 (24) 94
Any MOSI 62 (13) 167 (36) 207 (44) 172
MOSI  motor sign.
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creased speech/facial expression (  0.33, p  0.0001),
rigidity (  0.49, p  0.0001), posture/gait (  0.31, p 
0.0001), bradykinesia (  0.15, p  0.0001), and tremor
(  0.03, p  0.01) scores over time. Taking into account
the range of each domain score, the reported  coefficients
of annual change correspond to the following percentages
of the total possible score: speech/facial expression 4%, ri-
gidity 2.45%, posture/gait 3.90%, bradykinesia 3.75%, and
tremor 0.75%. Figure 2 gives a graphic representation of
the GEE results by plotting mean scores for each MOSI
domain and total MOSIs for each year of follow-up. It is
evident that, with the exception of tremor, which increases
only slightly, all MOSI domain scores increase consider-
ably over time.
In a Cox model that examined the incidence of any
MOSI, while simultaneously considering age, sex, educa-
tion, recruitment center, APOE, baseline mMMS, and
baseline BDRS, there was a significant APOE effect (risk
ratio [RR] 0.43, 95% CI 0.28 to 0.67) and baseline mMMS
effect (RR 0.93, 95% CI 0.89 to 0.97) (table 3). Therefore, 4
carriers and AD patients with higher baseline mMMS
scores were less likely to develop MOSIs. In terms of indi-
vidual MOSIs, women were less likely (or equivalently
men were more likely) to develop speech/facial expression
abnormalities. Subjects with higher mMMS at baseline
were less likely to develop all MOSI domains, and subjects
with lower BDRS (better functional status) were less likely
to develop bradykinesia. The 4 carriers were less likely to
develop all MOSI domains. Of note, there were no differ-
ences between the two APOE groups for gender (2  0.57,
p  0.45), education (t  0.93, p  0.36), baseline mMMS
scores (t  0.80, p  0.43), or baseline BDRS scores (t 
1.75, p  0.08). In addition, mean age for 4 carriers was
71.5 (SD 6.89) years and for non-4 carriers 71.9 (SD 9.38)
years (t  0.33, p  0.74). Despite some random fluctua-
tions for individual extrapyramidal signs, the RRs of the
five recruitment centers for the any MOSI category ranged
between 0.92 and 1.42. Overall, there were no significant
recruitment center effects for any of the MOSI domains.
Overall, 99 patients came to autopsy examination, 93%
of which had AD-type pathologic changes (87% received
the pathologic diagnosis of AD and 6% had senile changes
of the Alzheimer type). Dementia with Lewy bodies was
diagnosed in 22% (coexisting with AD-type changes in all
but 1 patient). Diagnosis of dementia with Lewy bodies
was present in 27% of autopsied patients with resting
tremor at any evaluation and in 19% of those who never
had resting tremor (2  0.43, p  0.51). Dementia with
Lewy bodies was diagnosed in 24% of patients who had
MOSIs at any point of their evaluation and in 13% of
patients who never manifested MOSIs (2  1.62, p 
0.20). Mean MOSI score (across all evaluations) was 6.6 for
patients with and 4.7 for patients without diagnosis of
dementia with Lewy bodies at autopsy (t  1.14, p 
0.26).
Discussion. In this cohort of early AD patients,
not all MOSIs behaved similarly during the course of
illness. Frequencies for speech/facial expression, ri-
gidity, posture/gait, and bradykinesia as well as inci-
dence rates were very similar to each other. Resting
tremor was the least frequent MOSI, which is in
accordance with other studies.5,6,12,27 Frequency of all
MOSIs was relatively uncommon at initial evalua-
tion, but their prevalence increased as disease pro-
gressed, again consistent with previous reports.5,6,12,13
This was true for all domains but in particular for
speech/facial expression, rigidity, posture/gait, and
Figure 1. Cumulative risk (1  cumulative survival) curves of developing individual domain motor signs (MOSIs) and
any MOSIs y-axes. The time axes (x) show years from first evaluation until development of signs (or last evaluation).
Figure 2. Mean scores for individual motor sign (MOSI) domains and total MOSIs (y axes) over the course of follow-up
in years (x axes). Regression lines are derived from the generalized estimating equation models.
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bradykinesia. Although tremor frequencies increased
too, the incidence rate for tremor was the lowest.
Few studies attempted to precisely characterize
patterns of progression of motoric signs in AD. Ac-
cording to a previous study that addressed this issue,
an AD patient’s overall level of parkinsonism at one
point in time was not a good predictor of that per-
son’s trajectory of change or a very good measure of
that person’s cumulative burden of parkinsonism
during the follow-up observation period.13 Therefore,
differences between reported rates in previous studies
may derive from each study using MOSI measures
cross-sectionally assessed at single points in time.
We attempted to address this issue by calculating
rates of MOSI change over time. Our data suggest
that all MOSIs do not behave similarly. The annual
increase in scores (of the total possible score) for
speech/facial expression, rigidity, posture/gait, and
bradykinesia ranged between 2.45 and 4%, whereas
the corresponding number for tremor was much
smaller (0.75%). These estimates were almost un-
changed even with the inclusion of various covari-
ates in the GEE models, including baseline MOSI
values. The calculated rates are somehow smaller
but quite close to previously reported ones.13 As a
perspective for our results, in a large community-
dwelling cohort of Parkinson disease patients, an-
nual increases for bradykinesia, gait/balance, and
rigidity ranged from 2 to 3.1%, but tremor did not
change.28 Annual increase of the total MOSI score
was 1.5% in that study as compared with 3% in the
current one. However, direct comparison of these two
rates is confounded by use of part of the UPDRS in
our cohort, different baseline levels of MOSIs, and
treatment with dopaminergic agents.
We investigated whether incidence of MOSIs dif-
fered by recruitment center by including it as a pre-
dictor in the analyses. The ethnic distribution of the
patients enrolled in the Predictors Study was heavily
weighted toward Caucasians (93%) with very few Af-
rican Americans (4.8%) or Hispanics (2.7%). There-
fore, we could address only the hypothesis that
development of MOSIs is different among different
Caucasian populations. Our results suggest no dif-
ference among Caucasian populations in terms of
MOSI occurrence. This was true for all MOSI do-
mains and for any MOSI overall. This would suggest
that differences in reported frequencies among previ-
ous studies12 are not a function of different popula-
tions but of other methodologic differences.
Carrying the 4 allele was associated with de-
creased risk for development of all MOSI domains.
We had previously published this association be-
tween the APOE genotype and MOSIs in a subset of
Table 3 Cox models predicting occurrence of individual MOSI domains and any MOSI overall
Parameter
Speech/facial
expression Tremor Rigidity Posture/gait Bradykinesia Any MOSI
Baltimore 1.33 0.78 1.51 1.13 1.29 1.42
(0.69–2.58) (0.28–2.16) (0.82–2.80) (0.61–2.11) (0.69–3.39) (0.86–2.34)
Boston 0.80 0.63 1.17 0.73 0.78 0.92
(0.32–1.99) (0.18–2.23) (0.55–2.49) (0.34–1.57) (0.34–1.77) (0.51–1.68)
Paris 0.66 0.73 2.05 1.46 1.68 1.15
(0.08–5.44) (0.08–6.57) (0.68–6.16) (0.53–4.04) (0.50–5.58) (0.49–2.70)
Larissa 1.68 1.98 0.96 1.60 0.98 1.31
(0.47–6.07) (0.48–8.11) (0.26–3.62) (0.41–6.24) (0.20–4.58) (0.52–3.30)
Females 0.48* 0.54 0.78 1.14 1.05 0.81
(0.26–0.88) (0.23–1.27) (0.45–1.34) (0.66–1.96) (0.61–1.82) (0.53–1.24)
Age 0.98 1.01 0.98 1.01 1.00 1.01
(0.95–1.02) (0.96–1.06) (0.95–1.01) (0.98–1.05) (0.97–1.04) (0.99–1.04)
Education 1.00 0.92 1.04 1.03 1.04 1.01
(0.92–1.08) (0.82–1.02) (0.97–1.11) (0.96–1.10) (0.97–1.12) (0.96–1.07)
4 carriers 0.50* 0.24* 0.37* 0.49* 0.43* 0.43*
(0.27–0.90) (0.10–0.61) (0.22–0.63) (0.28–0.83) (0.25–0.74) (0.28–0.67)
mMMS at baseline 0.87* 0.88* 0.91* 0.95* 0.94* 0.93*
(0.82–0.93) (0.81–0.96) (0.86–0.96) (0.90–1.00) (0.89–1.00) (0.89–0.97)
BDRS at baseline 1.03 0.81 1.11 1.11 1.20* 1.01
(0.56–1.24) (0.62–1.05) (0.95–1.29) (0.95–1.29) (1.02–1.41) (0.89–1.13)
Risk ratios (95% CI) are tabulated. Recruitment center risks have been calculated with the New York center as the reference.
*Significant (95% CI not including 1) association.
MOSI  motor sign; mMMS  Modified Mini-Mental State; BDRS  Blessed Dementia Rating Scale.
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this cohort (99 patients).29 We now confirm this find-
ing using a population that is much larger and fur-
ther note that the association holds for all types of
MOSIs. The presence of the 4 allele has been asso-
ciated with earlier age at disease onset, but whether
it is related to different AD clinical and phenotypic
subtypes is debatable because it may have a differ-
ent effect on the processes that determine rates of
progression. The APOE-related clinical heterogene-
ity30 may relate to underlying pathologic heterogene-
ity. Previous studies have indicated that frequency of
the 4 allele is significantly increased in AD with
Lewy bodies but not in pure Lewy body disease
(without concomitant AD changes)31 and that the 4
allele is associated with higher neurofibrillary tan-
gle32 and neuritic plaque33 burden in patients with
both AD-type and Lewy body-type pathology. Conse-
quently, presence of the 4 allele may indicate
mainly the AD type of underlying pathology,
whereas patients without the 4 allele may have a
relatively higher contribution of Lewy body pathol-
ogy to their clinical status. Therefore, AD patients
carrying the 4 allele may have lower risk for devel-
opment of MOSIs because of the lower burden of
concomitant Lewy body pathology.
We found that lower baseline cognitive performance
was associated with higher risk for all MOSIs and
lower baseline functional performance with higher risk
for bradykinesia. This is not unexpected as baseline
cognitive and functional scores may be a reflection of
disease stage at study entry and therefore may be sur-
rogates for disease severity (which is known to be asso-
ciated with MOSIs in AD).6,12,13 Finally, as compared
with men, women were at lower risk for developing
speech/facial expression abnormalities and resting
tremor. The importance of this finding is unclear as it
was present for only two MOSI domains and has not
been reported by previous studies.
Although there was a trend, no significant associ-
ation was detected between MOSI and the diagnosis
of dementia with Lewy bodies for the autopsied
cases. There was a stronger (but still not significant)
trend for the presence of dementia with Lewy bodies
at autopsy for patients who had resting tremor. Still,
diagnosis of dementia with Lewy bodies was not
present for 73% of patients with resting tremor and
for 76% of patients with MOSIs during any evalua-
tion. The underlying pathologic substrate of MOSIs
in AD is not clear. Lewy body changes are reported
in 18 to 55% of AD patients.12,34-36 Although some
studies have reported that AD patients with Lewy
bodies at autopsy (as compared with those without)
manifest more MOSIs during life,37,38 at least three
clinicopathologic studies, including one from this co-
hort, found no associations between Lewy bodies and
clinical MOSIs.39-41 In addition, it is known that
AD patients without Lewy bodies may manifest
MOSIs.42,43 Explanations other than Lewy bodies for
the presence of MOSIs in AD include extranigral
lesions involving mesocortical dopaminergic path-
ways,44 loss of striatal dopamine transporter sites,45
and reduced dopaminergic D2 receptors in the puta-
men.46 There are also studies that suggest that the
dopaminergic system may not be involved in the
MOSIs noted in AD.5,47 Alternatively, the dopaminer-
gic system may be involved but via AD pathology
itself. Senile plaques have been reported in the puta-
men, caudate, and substantia nigra,48 and neurofi-
brillary tangles have been noted in the substantia
nigra.49 In a previous clinicopathologic study that
involved some of the subjects from this cohort, we
reported an association between MOSIs and nigral
tangle pathology, in the absence of Lewy bodies.49
Finally, it is also possible that lesions outside the
extrapyramidal system may be responsible for the
MOSIs of the patients.
This study has limitations. First, we did not ad-
minister the full UPDRS, which may have restricted
the full range of impairment in particular for appen-
dicular bradykinesia. However, the items were se-
lected on the basis of earlier characterization of
MOSIs in AD. Second, assessment of MOSIs is often
difficult and rater related. It is also very difficult to
distinguish subtleties of various aspects of the mo-
toric examination (such as different types of tone,
velocity of movements, and gait abnormalities). How-
ever, we did not rely on clinical assessments but
instead used a scale that has been shown to have
good reliability properties and yields high rates of
agreements across interviewers. Also, the examina-
tions were performed mainly by experienced neurol-
ogists at large academic centers who were instructed
to rate the “parkinsonian” aspect of motor abnormal-
ities in AD patients. Still, it is possible that we had
not been able to accurately distinguish between the
various qualitative types of motoric disturbances.
Third, the long duration of follow-up (although it
may provide the advantage of more accurate record-
ing of disease course) results in use of multiple dif-
ferent raters of MOSIs over time, which increases
the variability of ratings of MOSIs. Fourth, AD pa-
tients were selected from tertiary care university
hospitals and specialized diagnostic and treatment
centers and therefore represent a nonrandom sample
of those affected by AD in the population. In addi-
tion, the proportion of African Americans and His-
panics in our sample was very small. Therefore, our
results cannot be generalized for population-based
AD or for all ethnicities. Fifth, although we used
survival analyses, which take advantage of variable
follow-up times, a longer duration of follow-up may
have provided a more complete conclusion about the
fraction of AD patients that remain MOSI-free dur-
ing the whole course of their disease.
Confidence in our findings is strengthened by sev-
eral factors. To our knowledge, this is the largest
study of its kind examining the issue of motoric ab-
normalities in AD supplying enough power for detec-
tion and more precise calculation of effects of
interest and the ability to control for potential con-
founders. A major contribution of the current analy-
ses lies in the careful diagnosis and clinical follow-up
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that patients received. Clinical diagnosis was based
on uniform application of widely accepted criteria via
a consensus diagnostic conference procedure. The
clinical diagnosis of AD was confirmed in a high
proportion of those who came to postmortem evalua-
tion: Ninety-three percent of autopsied patients had
AD-type pathologic changes. The patients were stud-
ied prospectively, which eliminates the potential bi-
ases inherent in deriving information from
retrospective chart reviews. Evaluations were per-
formed semiannually, which provides multiple as-
sessments of MOSIs and therefore permits more
accurate slope calculations. Our cohort had very high
rate of follow-up participation with very few missing
data. Clinical signs of interest were ascertained and
coded in a standardized fashion at each visit. Most
previous reports usually studied more impaired AD
patients, capturing the part of the disease course
corresponding to more advanced stages. Baseline
mMMS score for this cohort was 39.4 (and always
30), corresponding to a Folstein MMSE score of 21;
therefore, early AD patients were included so that
the cohort describes the full range of progression
over time. Patients were drawn from multiple loca-
tions, which increases generalizability of the find-
ings. Reported frequencies of MOSIs and reported
associations between MOSIs and other variables in
many previous studies are confounded by not taking
into account use of medications that may produce
MOSIs. We excluded patient evaluations with medi-
cations that could produce parkinsonism, which pro-
vides higher confidence that the occurrence of MOSIs
in the current study is strictly related to the under-
lying disease process.
These data provide a basis for expanding our un-
derstanding of the natural history of AD. MOSIs are
quite common and become more prominent as the
disease progresses. They also seem to occur univer-
sally, at least among Caucasian populations. How-
ever, not all MOSIs behave similarly. Tremor is the
least frequent and seems to be relatively indepen-
dent of disease progression. We found that 4 carri-
ers are at lower risk of developing MOSIs during the
course of AD, an association that has not been ex-
plored by other studies and warrants further investi-
gation. Knowledge of the natural course of MOSIs in
AD is important, given their predictive ability for
rates of cognitive decline and mortality and their
association with increased cost of care. The underly-
ing pathophysiologic substrate of their association
with the APOE genotype and of their occurrence in
general remains to be explored.
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